Evidences that estrogen receptor α interferes with adiponectin effects on breast cancer cell growth

Cell Cycle

Volumn 13, Issue 4, 2014, Pages 553-564

  Mauro, Loredana ^a   Pellegrino, Michele ^a   De Amicis, Francesca ^a   Ricchio, Emilia ^a   Giordano, Francesca ^a   Rizza, Pietro ^a   Catalano, Stefania ^a   Bonofiglio, Daniela ^a   Sisci, Diego ^a   Panno, Maria Luisa ^a   Andò, Sebastiano ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

Author keywords

Adiponectin; AdipoR1; APPL1; Breast cancer; Cell proliferation; Estrogen receptor alpha; IGF IR; MAPK

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MULTIPROTEIN COMPLEX; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR; ESTROGEN RECEPTOR ALPHA, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CELL NUCLEUS; CELL PROLIFERATION; CELL STRAIN MCF 7; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOLECULAR MECHANICS; ONCOGENE SRC; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSACTIVATION; UPREGULATION; BREAST TUMOR; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ADIPONECTIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ESTROGEN RECEPTOR ALPHA; HUMANS; MAP KINASE SIGNALING SYSTEM; PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVATION;

EID: 84896844800     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.27455     Document Type: Article

References (52)

1. MacDougald OA, Burant CF. The rapidly expanding family of adipokines. Cell Metab 2007; 6:159-61; PMID:17767903; http://dx.doi.org/10.1016/j.cmet.2007. 08.010
2. Andò S, Catalano S. The multifactorial role of leptin in driving the breast cancer microenvironment. Nat Rev Endocrinol 2012; 8:263-75; PMID:22083089; http://dx.doi.org/10.1038/nrendo.2011.184
3. Brochu-Gaudreau K, Rehfeldt C, Blouin R, Bordignon V, Murphy BD, Palin MF. Adiponectin action from head to toe. Endocrine 2010; 37:11-32; PMID:20963555; http://dx.doi.org/10.1007/s12020-009-9278-8
4. Matsubara M, Maruoka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 2002; 147:173-80; PMID:12153737; http://dx.doi.org/10.1530/eje.0. 1470173
5. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46:459-69; PMID:12687327
6. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86:1930-5; PMID:11344187; http://dx.doi.org/10.1210/jc.86.5.1930
7. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 277:25863-6; PMID:12032136; http://dx.doi.org/10.1074/jbc.C200251200
8. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8:731-7; PMID:12068289; http://dx.doi.org/10.1038/nm724
9. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6:772-83; PMID:16998510; http://dx.doi.org/10.1038/nri1937
10. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev 2012; 33:547-94; PMID:22547160; http://dx.doi.org/10.1210/er.2011-1015
11. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 2001; 98:2005-10; PMID:11172066; http://dx.doi.org/10.1073/pnas.98.4.2005
12. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423:762-9; PMID:12802337; http://dx.doi.org/10.1038/nature01705
13. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26:439-51; PMID:15897298; http://dx.doi.org/10.1210/er.2005-0005
14. Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, Ramos FJ, Fang Q, Christ-Roberts CY, Hong JY, Kim RY, et al. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol 2006; 8:516-23; PMID:16622416; http://dx.doi.org/10.1038/ncb1404
15. Lee M-H, Klein RL, El-Shewy HM, Luttrell DK, Luttrell LM. The adiponectin receptors AdipoR1 and AdipoR2 activate ERK1/2 through a Src/Ras-dependent pathway and stimulate cell growth. Biochemistry 2008; 47:11682-92; PMID:18842004; http://dx.doi.org/10.1021/bi801451f
16. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer 2006; 94:1221-5; PMID:16570048; http://dx.doi.org/10.1038/sj.bjc.6603051
17. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, Noguchi S. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 2003; 9:5699-704; PMID:14654554
18. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004; 89:1102-7; PMID:15001594; http://dx.doi.org/10.1210/jc.2003-031804
19. Körner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, Bullen J, Neuwirth A, Tseleni S, Mitsiades N, et al. Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 2007; 92:1041-8; PMID:17192291; http://dx.doi.org/10.1210/jc.2006-1858
20. Kang JH, Lee YY, Yu BY, Yang BS, Cho KH, Yoon DK, Roh YK. Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res 2005; 28:1263-9; PMID:16350853; http://dx.doi.org/10.1007/BF02978210
21. Dos Santos E, Benaitreau D, Dieudonne MN, Leneveu MC, Serazin V, Giudicelli Y, Pecquery R. Adiponectin mediates an antiproliferative response in human MDA-MB 231 breast cancer cells. Oncol Rep 2008; 20:971-7; PMID:18813842
22. Grossmann ME, Nkhata KJ, Mizuno NK, Ray A, Cleary MP. Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer 2008; 98:370-9; PMID:18182989; http://dx.doi.org/10.1038/sj.bjc.6604166
23. Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y, Pecquery R. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun 2006; 345:271-9; PMID:16678125; http://dx.doi.org/10.1016/j.bbrc.2006.04.076
24. Jardé T, Caldefie-Chézet F, Goncalves-Mendes N, Mishellany F, Buechler C, Penault-Llorca F, Vasson MP. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr Relat Cancer 2009; 16:1197-210; PMID:19661131; http://dx.doi.org/10.1677/ERC-09-0043
25. Treeck O, Lattrich C, Juhasz-Boess I, Buchholz S, Pfeiler G, Ortmann O. Adiponectin differentially affects gene expression in human mammary epithelial and breast cancer cells. Br J Cancer 2008; 99:1246-50; PMID:18827813; http://dx.doi.org/10.1038/sj.bjc.6604692
26. Pfeiler GH, Buechler C, Neumeier M, Schäffler A, Schmitz G, Ortmann O, Treeck O. Adiponectin effects on human breast cancer cells are dependent on 17-beta estradiol. Oncol Rep 2008; 19:787-93; PMID:18288417
27. Landskroner-Eiger S, Qian B, Muise ES, Nawrocki AR, Berger JP, Fine EJ, Koba W, Deng Y, Pollard JW, Scherer PE. Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo. Clin Cancer Res 2009; 15:3265-76; PMID:19447867; http://dx.doi.org/10.1158/1078-0432.CCR-08-2649
28. Sflomos G, Brisken C. A new Achilles Heel in breast cancer? Oncotarget 2013; 4:1126-7; PMID:23907591
29. Mauro L, Surmacz E. IGF-I receptor, cell-cell adhesion, tumour development and progression. J Mol Histol 2004; 35:247-53; PMID:15339044; http://dx.doi.org/10.1023/B:HIJO.0000032356.98363.a2
30. Simoncini T, Genazzani AR. Non-genomic actions of sex steroid hormones. Eur J Endocrinol 2003; 148:281-92; PMID:12611608; http://dx.doi.org/10.1530/eje. 0.1480281
31. Schäffler A, Schölmerich J, Buechler C. Mechanisms of disease: adipokines and breast cancer - endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat Clin Pract Endocrinol Metab 2007; 3:345-54; PMID:17377617; http://dx.doi.org/10.1038/ncpendmet0456
32. Park J, Euhus DM, Scherer PE. Paracrine and endocrine effects of adipose tissue on cancer development and progression. Endocr Rev 2011; 32:550-70; PMID:21642230; http://dx.doi.org/10.1210/er.2010-0030
33. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89:2548-56; PMID:15181022; http://dx.doi.org/10.1210/jc. 2004-0395
34. Trujillo ME, Scherer PE. Adiponectin - journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005; 257:167-75; PMID:15656875; http://dx.doi.org/10.1111/j.1365-2796.2004.01426.x
35. Jardé T, Perrier S, Vasson MP, Caldefie-Chézet F. Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer 2011; 47:33-43; PMID:20889333; http://dx.doi.org/10.1016/j.ejca.2010.09.005
36. Wang Y, Lam JB, Lam KS, Liu J, Lam MC, Hoo RL, Wu D, Cooper GJ, Xu A. Adiponectin modulates the glycogen synthase kinase-3β/β-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 2006; 66:11462-70; PMID:17145894; http://dx.doi.org/10. 1158/0008-5472.CAN-06-1969
37. Chen X, Wang Y. Adiponectin and breast cancer. Med Oncol 2011; 28:1288-95; PMID:20625941; http://dx.doi.org/10.1007/s12032-010-9617-x
38. Lanzino M, Morelli C, Garofalo C, Panno ML, Mauro L, Andò S, Sisci D. Interaction between estrogen receptor alpha and insulin/IGF signaling in breast cancer. Curr Cancer Drug Targets 2008; 8:597-610; PMID:18991569; http://dx.doi.org/10.2174/156800908786241104
39. Song RX, Chen Y, Zhang Z, Bao Y, Yue W, Wang JP, Fan P, Santen RJ. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. J Steroid Biochem Mol Biol 2010; 118:219-30; PMID:19815064; http://dx.doi.org/10. 1016/j.jsbmb.2009.09.018
40. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001; 22:153-83; PMID:11294822; http://dx.doi.org/10.1210/er.22.2.153
41. Deepa SS, Dong LQ. APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab 2009; 296:E22-36; PMID:18854421; http://dx.doi.org/10. 1152/ajpendo.90731.2008
42. Murphy LC, Weitsman GE, Skliris GP, Teh EM, Li L, Peng B, Davie JR, Ung K, Niu YL, Troup S, et al. Potential role of estrogen receptor alpha (ERalpha) phosphorylated at Serine118 in human breast cancer in vivo. J Steroid Biochem Mol Biol 2006; 102:139-46; PMID:17092701; http://dx.doi.org/10.1016/j.jsbmb. 2006.09.021
43. Luttrell LM. 'Location, location, location': activation and targeting of MAP kinases by G protein-coupled receptors. J Mol Endocrinol 2003; 30:117-26; PMID:12683936; http://dx.doi.org/10.1677/jme.0.0300117
44. De Amicis F, Russo A, Avena P, Santoro M, Vivacqua A, Bonofiglio D, Mauro L, Aquila S, Tramontano D, Fuqua SA, et al. In vitro mechanism for downregulation of ER-α expression by epigallocatechin gallate in ER+/PR+ human breast cancer cells. Mol Nutr Food Res 2013; 57:840-53; PMID:23322423; http://dx.doi.org/10.1002/mnfr.201200560
45. Rovito D, Giordano C, Vizza D, Plastina P, Barone I, Casaburi I, Lanzino M, De Amicis F, Sisci D, Mauro L, et al. Omega-3 PUFA ethanolamides DHEA and EPEA induce autophagy through PPARγ activation in MCF-7 breast cancer cells. J Cell Physiol 2013; 228:1314-22; PMID:23168911; http://dx.doi.org/10. 1002/jcp.24288
46. Panno ML, Giordano F, Rizza P, Pellegrino M, Zito D, Giordano C, Mauro L, Catalano S, Aquila S, Sisci D, et al. Bergapten induces ER depletion in breast cancer cells through SMAD4-mediated ubiquitination. Breast Cancer Res Treat 2012; 136:443-55; PMID:23053665; http://dx.doi.org/10.1007/s10549-012-2282-3
47. Mauro L, Catalano S, Bossi G, Pellegrino M, Barone I, Morales S, Giordano C, Bartella V, Casaburi I, Andò S. Evidences that leptin up-regulates E-cadherin expression in breast cancer: effects on tumor growth and progression. Cancer Res 2007; 67:3412-21; PMID:17409452; http://dx.doi.org/10.1158/0008- 5472.CAN-06-2890
48. Guido C, Panza S, Santoro M, Avena P, Panno ML, Perrotta I, Giordano F, Casaburi I, Catalano S, De Amicis F, et al. Estrogen receptor beta (ERβ) produces autophagy and necroptosis in human seminoma cell line through the binding of the Sp1 on the phosphatase and tensin homolog deleted from chromosome 10 (PTEN) promoter gene. Cell Cycle 2012; 11:2911-21; PMID:22810004; http://dx.doi.org/10.4161/cc.21336
49. Mauro L, Pellegrino M, Lappano R, Vivacqua A, Giordano F, Palma MG, Andò S, Maggiolini M. E-cadherin mediates the aggregation of breast cancer cells induced by tamoxifen and epidermal growth factor. Breast Cancer Res Treat 2010; 121:79-89; PMID:19593637; http://dx.doi.org/10.1007/s10549-009- 0456-4
50. Guido C, Whitaker-Menezes D, Lin Z, Pestell RG, Howell A, Zimmers TA, Casimiro MC, Aquila S, Ando' S, Martinez-Outschoorn UE, et al. Mitochondrial fission induces glycolytic reprogramming in cancer-associated myofibroblasts, driving stromal lactate production, and early tumor growth. Oncotarget 2012; 3:798-810; PMID:22878233
51. De Amicis F, Zupo S, Panno ML, Malivindi R, Giordano F, Barone I, Mauro L, Fuqua SA, Andò S. Progesterone receptor B recruits a repressor complex to a half-PRE site of the estrogen receptor alpha gene promoter. Mol Endocrinol 2009; 23:454-65; PMID:19147702; http://dx.doi.org/10.1210/me.2008-0267
52. Casaburi I, Avena P, Lanzino M, Sisci D, Giordano F, Maris P, Catalano S, Morelli C, Andò S. Chenodeoxycholic acid through a TGR5-dependent CREB signaling activation enhances cyclin D1 expression and promotes human endometrial cancer cell proliferation. Cell Cycle 2012; 11: 2699-710; PMID:22751440; http://dx.doi.org/10.4161/cc.21029